Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis and Metastatis
AssigneeThe Regents of the University of California
InventorsRobert E. Reiter, Zev Wainberg
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
Claims10
1-12. (canceled)
An antibody or fragment thereof that will specifically bind to domain 4 of N-cadherin, the same antigenic determinant of N-cadherin, in vivo or in vitro, as does the monoclonal antibody produced by the hybridoma cell line deposited at the American Type Culture Collection having ATCC Accession No. PTA-9388, wherein the antibody or fragment thereof comprises (i) a heavy chain comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO:3, and/or (ii) a light chain comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO:4.
21-42. (canceled)
Dependencies are inferred from the claim text.